Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
135 hedge funds and large institutions have $1.09B invested in Genomic Health, Inc. in 2017 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 48 increasing their positions, 42 reducing their positions, and 20 closing their positions.
1,493% more call options, than puts
Call options by funds: $3.22M | Put options by funds: $202K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
14% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 42
8% more capital invested
Capital invested by funds: $1.01B → $1.09B (+$76.9M)
5% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 20
1% more funds holding
Funds holding: 134 → 135 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$14.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.9M |
| 3 |
Renaissance Technologies
New York
|
+$4.51M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.22M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$2.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.94M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$4.84M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.88M |
| 4 |
SIM
Spark Investment Management
New York
|
-$1.69M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$1.54M |
GHDX Hedge Fund Activity: Q4 2017 in Review
135 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q4 2017, worth a combined $1.09B — up 7.6% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new GHDX positions and 20 closed out — a net gain of 1 holder — while 48 added to existing stakes and 42 trimmed.
The largest buyer was Columbia Wanger Asset Management, adding an estimated $14.2M. The largest seller was BlackRock, cutting an estimated $7.94M.
- 135 institutional investors held Genomic Health, Inc. (GHDX) as of Q4 2017, up from 134 in Q3 2017.
- Funds reported $1.09B of Genomic Health, Inc. stock for Q4 2017, up 7.6% quarter-over-quarter.
- 21 funds opened new Genomic Health, Inc. positions in Q4 2017 and 20 closed out, a net change of +1 holder.
- The largest Genomic Health, Inc. buyer in Q4 2017 was Columbia Wanger Asset Management, an estimated $14.2M added.
- The largest Genomic Health, Inc. seller in Q4 2017 was BlackRock, an estimated $7.94M sold.
Based on aggregated 13F filings for Q4 2017.